Evommune (EVMN) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Evommune is the larger company by market cap ($187.6 million vs $179.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | PEPG |
|---|---|---|
| Share price | $5.17 | $2.60 |
| Market cap | $187.63M | $179.84M |
| 1-day change | -12.82% | +2.77% |
| YTD return | -69.80% | -60.06% |
| 1-year return | — | -46.83% |
| EPS (TTM) | $-3.68 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.00M | — |
| Revenue growth (YoY) | +85.71% | — |
| Net income (latest FY) | $-68.87M | $-89.66M |
| Operating margin | -623.62% | — |
| Net margin | -529.77% | — |
| 52-week high | $33.20 | $7.80 |
| 52-week low | $5.09 | $1.31 |
| Distance from 52-week high | -84.43% | -66.67% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +331.91% | +291.92% |
| Average volume | 685.46K | 864.38K |
| Shares outstanding | 36.29M | 69.17M |
| Employees | 48 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
EVMN vs PEPG FAQ
Which is bigger, Evommune or PepGen?
Evommune (EVMN) is larger, with a market capitalization of $187.63M compared with $179.84M for PepGen (PEPG).
Are Evommune and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.